Objective
Novel concepts to control newly emerging and highly pathogenic Marek's disease virus (vv+ MDV-1) are needed. Different antigen formulations, routes of vaccination, and biological adjuvant will be tested. DNA vaccines encoding MDV-1 antigens expressed in all stages of the virus' life cycle (lytic, latent, tumour stage) will be constructed, with an emphasis on antigens inducing a cytotoxic T cell response. The same proteins will also be expressed by recombinant Sindbis viruses. Modified live vaccines derived from a vv+ MDV-1 strain with a deletion in gB or gM shall be constructed using the bacterial artificial chromosome technique. The routes of vaccination will be
1) in-ovo vaccination and
2) vaccination of 1- day-old chickens via various routes. The cytokine profiles after MDV-1 infection will be analysed by developing new tools and test systems, and rational approaches to immune modulation using biological adjuvant will be developed and tested.
Call for proposal
Data not availableFunding Scheme
CSC - Cost-sharing contractsCoordinator
17498 Insel Riems
Germany
Participants (7)
6701 Szeged
37380 Monnaie , Nouzilly
84246 Bratislava
RG16 0NN Newbury
50250 Bet Dagan
27472 Cuxhaven
80539 Muenchen